Total: $192.76M

Company

Location

Date

Amt. (M)

Details


Altacor

Cambridge, UK

2/9

£1.9 ($3.1)

Closed a second $3.1M tranche of a $5.4M equity fund raising led by Clive Austin of NVM Private Equity and including Enterprise Ventures' RisingStars Growth Fund and Beringea

Cellerix SA

Tres Cantos, Spain

2/28

€18 ($24.8)

Cellerix raised $24.8M in a financing completed just before the announcement of its merger agreement with TiGenix NV

Chimerix Inc.

Durham, N.C.

2/15

$45

Chimerix raised $45M in a Series F financing led by New Leaf Venture Partners; other investors were Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management Co., Frazier Healthcare, Pappas Ventures and Morningside Group

Conatus Pharmaceuticals Inc.

San Diego

2/14

$20

Conatus raised $20M in a Series B financing led by AgeChem Venture Fund and including Aberdare Ventures, Advent Venture Partners, Bay City Capital, Bilde Healthcare Partners and Roche Venture Fund

Diartis Pharmaceuticals Inc.

Mountain View, Calif.

2/22

ND

Diartis raised an undisclosed amount in a Series A round from Index Ventures, Amunix Inc. and private investors

Eviagenics

Paris

2/10

€1.3 ($1.8)

Eviagenics closed a Series A round raising $1.8M

Ocular Therapeutix Inc.

Bedford, Mass.

2/4

$14

Ocular raised $14M in a Series D round led by Ascension Health Ventures, with participation by Polaris Ventures, SV Life Sciences and Versant Ventures

Scil Proteins GmbH

Halle, Germany

2/3

€24 ($33.1)

Scil raised $33.1M in a financing round with BioNet Holding GmbH

SironRX Therapeutics Inc.

Cleveland

2/9

$0.5

SironRX secured a combined investment commitment of $500,000 from JumpStart Ventures and the Cleveland Clinic

SymBio Pharmaceuticals Ltd.

Tokyo

2/28

$24

SymBio completed a $24M Series E round led by existing shareholders Cephalon Inc. and JAFCO Co. Ltd.

to-BBB Holding BV

Leiden, the Netherlands

2/4

€4 ($5.46)

to-BBB closed its Series B round with investors Dutch Healthcare Investors of Jonghoud International BV and the Boston Life Science fund of the Industrial Bank of Taiwan Management Corp.; existing investors Aescap Venture and Antea Participaties also participated

Versartis Inc.

Mountain View, Calif.

2/17

$21

Versartis raised $21M in a Series B round


Notes:

Currency conversions are based on exchange rates at the time of the deal.

** Denotes the date the item ran in BioWorld International.

The date indicated refers to the BioWorld Today issue in which the news item can be found.

ND = Not disclosed.